CXCR2 modulators: a patent review (2009 - 2013)
1Department of Medicinal Chemistry, Merck Research Laboratories , 126 E. Lincoln Ave, RY800-D101, Rahway, NJ 07065-0900 , USA +1 732 594 1733 ; +1 732 594 9490 ; michael.dwyer@merck.com.
Novel small-molecule antagonists targeting CXC chemokine receptor 2 (CXCR2) show promise for inflammatory conditions. Patent and literature reviews highlight compounds and their biological data, guiding future therapeutic development.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- CXC chemokine receptor 2 (CXCR2) antagonists are crucial for managing inflammatory conditions.
- Recent clinical trials show promising activity for CXCR2 antagonists in pulmonary diseases.
Purpose of the Study:
- To review patent publications and peer-reviewed literature on novel CXCR2 antagonists from 2009-2013.
- To highlight representative compounds and their biological characterization.
Main Methods:
- Comprehensive review of patent literature (2009-2013).
- Analysis of emerging peer-reviewed disclosures.
- Identification and characterization of preferred CXCR2 antagonist compounds.
Main Results:
- Numerous companies patented novel CXCR2 receptor antagonists between 2009 and 2013.
- Representative compounds from patent applications were identified.
- Biological data for selected compounds were compiled.
Conclusions:
- Many newly described CXCR2 antagonists are analogs of existing clinical candidates.
- Future clinical trial data will determine the therapeutic potential of CXCR2 antagonists for inflammatory disorders.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017